-
Product Insights
Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewNet Present Value Model: Xencor Inc’s izuralimab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Bristol-Myers Squibb Co’s BMS-986218
Empower your strategies with our Net Present Value Model: Bristol-Myers Squibb Co's BMS-986218 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-001 in Neuroinflammation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KB-001 in Neuroinflammation Drug Details: KB-001 is under development for the treatment of Alzheimer's disease,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EOS-984 in Advanced Malignancy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EOS-984 in Advanced Malignancy Drug Details: EOS-984 is under development for the treatment of advanced malignancies....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Belrestotug in Melanoma Drug Details:EOS-448 is under development for the treatment of solid tumors,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant hydrochloride in Melanoma Drug Details: EOS-850 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Belrestotug in Non-Small Cell Lung Cancer Drug Details:EOS-448 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BIIB-080 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BIIB-080 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIIB-080 in Dementia Associated With Alzheimer's Disease Drug...